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Abstract
Emerging research within the field of personalised medicines has aimed to enhance patient treatment through the use of
pharmaceutical products that are customised to the individual needs and preferences of the patient. The currently domi-
nant production platforms of pharmaceutical products, however, regard a mass production paradigm and are thus unfea-
sible for the production and provision of personalised medicines. The production platforms are not designed or are
intended for a customisation context. Operating such a context with the current supply chain entails challenges such as
increasing costs, time to patient and efforts in quality assurance activities. To address these challenges, this paper pre-
sents four reconfigured pharmaceutical supply chain designs. A qualitative operational performance assessment elicits
the strengths and weaknesses of the respective supply chain design operating in a customisation context. The results
suggest that a later point of variegation, that is, the point in the supply chain where the final customisation is achieved,
can relieve the operational effort of the stakeholders in the supply chain while providing the benefits of personalised
medicines, that is, an enhanced treatment outcome of the patient. A trade-off remains, however, between the supply
chain’s decreased operational effort and degree of necessary reconfigurations, such as introducing new functions to sta-
keholder operation, reallocating activities to other stakeholders or educating stakeholders.
Keywords
mass customisation, personalised medicines, pharmaceutical supply chain design, supply chain reconfiguration, integrated
design
Introduction
An emerging patient-centric approach to treatment pro-
vision has the core purpose of enhancing the treatment
outcome of the patient, emphasising the treatment’s
safety and effectiveness (Ahmed et al., 2016; Meyer,
2004). Personalised medicines, that is, treatments custo-
mised to the individual needs and preferences of the
patient are widely researched with patient-centricity in
mind (Crommelin et al., 2011).
Recent pharmacological research supports a shift
towards a paradigm of personalised medicines, thereby
providing tools to map patients’ biological attributes.
Patient-centric treatments are established by translating
their biological, environmental and behavioural attri-
butes into treatment design parameters (Govender
et al., 2020a, 2020b). The current pharmaceutical prod-
ucts and production system is, however, neither
designed nor intended for personalised medicines. The
product design still embraces a one-size-fits-all design,
as mass production in a batch manner permeates the
operational mode of pharmaceutical production to pro-
duce large volumes of identical product variants
(Wilson, 2016). A transition towards pharmaceutical
product customisation implies decreased production
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volumes, increased product variants and design complex-
ity – the current production platforms’ technical capabil-
ity and economic feasibility is surpassed (Govender et al.,
2020a; Siiskonen et al., 2020; Wilson, 2016). Without fea-
sible production and provision, customised pharmaceuti-
cal products cannot reach the patient, thereby preventing
enhancement of the treatment outcome.
In the pharmaceutical product context, mass custo-
misation is discussed as a solution for a paradigm of
customised pharmaceutical products, meaning ‘design-
ing, producing and distributing customised pharmaceu-
tical products in an economically feasible manner’
(Govender et al., 2020a); however, there is a lack of
extensive mass customisation discussions in a pharma-
ceutical product context in the literature. Past studies
considered patient-centric product design by introdu-
cing novel technologies such as additive manufacturing
(e.g. Goyanes et al., 2015; Norman et al., 2017), but
they lacked technical and economic realisability or stra-
tegic product provision. When conducting product
improvement tasks, however, it is important to consider
an integrated approach to product customisation as well
as feasible production and provision (Prasad, 2016).
Sequential product development runs a risk of late and
costly changes propagating from product design
(Landahl et al., 2020). A few notable publications discuss
production system design to manage the growing com-
plexity of the product portfolio as a consequence of
product customisation (i.e. decreasing product volumes
and increasing product variants), for example, Srai et al.
(2015), O’Connor et al. (2016) and Harrington et al.
(2016). These studies consider refined mass production
by proposing novel technologies enhancing the efficiency
of manufacturing while preserving current production
platform design as well as a one-size-fits-all product
design and omitting the discussion of product provision.
To the best of our knowledge, there is an absence of
system-level analysis of current pharmaceutical supply
chain designs operating in a customisation context
beyond point-based solutions to product or production
system design. Current approaches have either consid-
ered patient-centric product design for the optimization
of individual treatment (Goyanes et al., 2015; Norman
et al., 2017), failing to incorporate any consequential
analysis on the technical and economic feasibility from
wider production and provision perspective. On the
other hand, the increasing volume/variety complexity
challenge in pharmaceutical production has been
addressed by introducing novel technologies into pro-
duction optimization (Harrington et al., 2016;
O’Connor et al., 2016; Srai et al., 2015). These studies
have rather considered a refined mass production para-
digm still considering a one-size-fits-all product design
and disregarding a wider supply chain perspective and
product provision. Product improvement tasks require
concurrent design to eliminate risks of late and costly
changes propagating from product design to respective
domains (Landahl et al., 2020; Prasad, 2016), thus, a
mass customisation paradigm for pharmaceutical prod-
ucts requires integrated approaches to patient-centric
product design, production system design and feasible
product provision.
This study is guided by the following research ques-
tions: RQ1 is formulated as: What are the operational
weaknesses of the current pharmaceutical supply chain
design when operated in a pharmaceutical product cus-
tomisation context? A system-level end-to-end assess-
ment of the currently operating pharmaceutical supply
chain in a customisation context is provided and opera-
tional criteria are collected for a performance assess-
ment to elicit weaknesses. Thus, RQ2 is: Which
operational performance criteria can be used to assess
the performance of the pharmaceutical supply chain
operating in a customisation context? The weaknesses
of the currently operating supply chain in a customisa-
tion context are addressed, and RQ3 is thus formulated
as: How can the pharmaceutical supply chain be recon-
figured to address the operational weaknesses of the
currently operating pharmaceutical supply chain? This
question suggests reconfigured pharmaceutical supply
chain designs operating in the customisation context
and assesses their performance.
The remainder of the paper is organised as follows:
Section ‘‘Research approach’’ describes the research
approach, scoping and delimitations of the study. A
state of the art review of essential concepts is provided
in Section ‘‘State of the art’’. Section ‘‘The pharmaceu-
tical supply chain’’ details the pharmaceutical supply
chain. Section ‘‘Results’’ presents the results of the
study which are discussed in Section ‘‘Discussion’’ pro-
viding an answer to each research question as well as
discussing limitations of this study and proposing fur-
ther research to address these limitations. Section
‘‘Conclusions and future work’’ concludes the findings
and highlights opportunities for future research.
Research approach
The industrial challenge described in the Introduction-
section, that is, the currently dominating mass-
production operating mode for pharmaceutical prod-
ucts is challenging a paradigm of personalised medi-
cines, constituted the starting point of this research.
Key literature on current pharmaceutical production
and its challenges in a customisation context was scruti-
nised to establish a research gap, that is, the lack of
end-to-end system-level analysis of pharmaceutical pro-
duction in a customisation context (e.g. Ahmed et al.,
2016; Govender et al., 2020a; Harrington et al., 2016;
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O’Connor et al., 2016; Siiskonen et al., 2020; Srai et al.,
2015; Wilson, 2016).
The currently operating pharmaceutical supply chain
was mapped, the as-is design of the supply chain, using
literature describing this (e.g. Aitken, 2016; Derecque-
Pois, 2010; Olson, n.d.; Savage et al., 2006; Shah, 2004).
An analytical assessment of operational consequences
was performed on the as-is design, when operating this
in a customisation context, to further verify the indus-
trial challenge posed at the beginning and to elicit the
weaknesses of operating the as-is design in a customisa-
tion context. For the assessment, a set of operational
performance criteria was collected from the literature
concerning current pharmaceutical production in a cus-
tomisation context. Due to the scarcity of this litera-
ture, the literature on mass customisation as well as
product portfolio complexity and operational perfor-
mance in industrial contexts were reviewed to comple-
ment the list of criteria. For the initial collection of
performance criteria, the following studies were used as
guidance (Govender et al., 2020a; Price Waterhouse
Coopers, 2011; Rantanen and Khinast, 2015; Shah,
2004; Stäblein et al., 2010; Trattner et al., 2019; Wilson,
2016). The initial set of criteria was, furthermore, dis-
cussed with a group of industrial practitioners and
refined accordingly. As the operational performance
assessment method, the concept screening matrix by
Ulrich and Eppinger (2012) was used.
Novel reconfigurations to the pharmaceutical supply
chain were then proposed to address the operational
weaknesses of the as-is design in a customisation con-
text. To establish reconfigurations, successful business
models operating in a mass customisation paradigm or
managing complex product portfolios were explored.
Search terms such as ‘successful business models’ and
‘customisation’ and ‘large product variety’ were used to
explore these business models. As a search engine the
University library was used, and further, to expand the
scope beyond academic research Google search was
used. Due to the lack of supply chain models operating
in a pharmaceutical customisation context, the focus
was on supply chains of discrete goods. As selection cri-
teria, business models with final assembly occurring at
various phases of the supply chain was used to inspire
to a large span of design variations, that is, applying the
mass customisation principle postponement. Business
models providing inspiration incorporated the ones
operated by Walmart Inc., the restaurant franchise
Subway and the computer technology company Dell
(Bhasin, 2019a, 2019b; Lutz, 2014).
Theory synthesisation occurred by the means of
adapting the studied business models into the pharma-
ceutical supply chain context, that is, proposing the
supply of pharmaceutical products according to the
business models explored but within the context of a
pharmaceutical supply chain regarding supply chain
actors, activities, product nature and so forth. These
models were further refined after discussing these mod-
els with a group of industrial practitioners resulting in
final reconfigurations of the pharmaceutical supply
chain.
Finally, the operational performance of these recon-
figured supply chain designs was assessed by using the
same set of performance criteria as for assessing the
performance of the as-is design. Likewise, the concept
screening matrix by Ulrich and Eppinger (2012) was
used as a method for performance assessment.
Scoping and delimitations
This section clarifies the assumptions and delimitations
before conducting the study.
Pharmaceutical product customisation refers to
designing and producing personalised medicines, and
thus the terms customised pharmaceutical products and
personalised medicines are used interchangeably. This
study only considers customisation of the physical
product from a technical perspective, excluding custo-
mised patient caretaking approaches.
Pharmaceutical products regard prescription prod-
ucts (both brand-name and generic drugs) and embrace
a solid oral dosage form, specifically a tablet design.
Patient-centric product design is not explicitly studied
but rather, the consequence of these designs on the
operation of the pharmaceutical supply chain is stud-
ied, that is, the growing complexity of the product port-
folio on supply chain management. This paper will not
study the concept of complexity per se, but rather use
the term when addressing the growing product variety
– product volume complexity of the product portfolio.
Explicit knowledge on the absolute level of customi-
sation for pharmaceutical products cannot be found. In
this study, the level of customisation of a prescription
acquired by the patient resembles a pre-assembled pill
organiser. This paper’s supply chain scenarios aimed at
operating in a customisation context will embrace the
same final product variety. Furthermore, in any custo-
misation scenario, customer interference with the treat-
ment before administration is assumed to be non-
existent and outside the scope. Furthermore, this study
considers no intravariability of patient prescriptions
over time, meaning that patient prescriptions do not
change over time since no longer time periods are con-
sidered in this study.
This paper primarily considers the supply chain
actors physically in contact with the pharmaceutical
product, which includes the secondary manufacturer,
wholesaler, retailer and customer. The primary manu-
facturer, the producer of the raw materials for the phar-
maceutical product is disregarded in this study. The
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assumption is that no design changes are made on a
molecular level, and hence the primary production
might operate as-is in all scenarios analysed in this
study.
The customer group is solely represented by the
patient; however, the healthcare system regards a com-
plex network in which society, a country’s healthcare
system, authorities, etc. can be considered customers.
Healthcare system operation exceeds the scope of this
study due to the lack of a global healthcare system, and
thus decisions regarding reconfiguration must be made
on a local level integrated to any global-level decisions.
Compliance to the regulatory framework will be incor-
porated when assessing the performance of the supply
chain design. The regulatory framework is assumed to
be static and the consequences of compliance in a cus-
tomisation context are assessed. For ongoing research
discusses the reshaping of regulatory compliance
approaches for a paradigm of personalised medicines
the reader is referred to, for example, Rantanen and
Khinast (2015).
State of the art
This section reviews essential literature for the study. A
brief description of personalised medicines is given
along with the challenges of personalised medicines in a
currently operating pharmaceutical production para-
digm. The consequential complexity challenge of a
paradigm of personalised medicines is discussed and
finally, the topic of mass customisation as a probable
remedy for the complexity challenge is addressed. This
section is concluded by clarifying research gaps
addressed in this study, based on the before reviewed
literature.
Personalised medicines
Personalised medicines refer to treatments, that is, the
dosage form such as tablets or capsules, that are custo-
mised to the individual needs and preferences of the
patient (Govender et al., 2020a, 2020b). The core pur-
pose of personalised medicines is to enhance the treat-
ment outcome of the patient, that is, delivering safe and
effective treatments (Ahmed et al., 2016).
The current production paradigm of pharmaceutical
products
Despite the emerging personalised medicines research, a
mass production-dominated paradigm of pharmaceuti-
cal products challenges the wider establishment of per-
sonalised medicines. A mass production (MP) paradigm
implies a batch-based production of pharmaceutical
products embracing a one-size-fits-all design. This perme-
ates the treatment prescription procedure which com-
monly provides the physician with the choice between 4
and 6 product variants. This does not optimise the
patient’s therapeutic outcome, but it has been argued that
increasing the number of product variants is not economi-
cally feasible production-wise (Wilson, 2016).
An MP paradigm of pharmaceutical products argu-
ably manages a complex product portfolio. To illustrate
this product portfolio complexity, Wilson (2016) exem-
plifies that manufacturers might produce 10–40 variants
of a single drug substance when factoring not only vari-
ous dose strengths but also product formulations (e.g.
solid or liquid). When packaging the products, the
number of variants is increased 10-fold since manufac-
turers serve markets in several countries, which pose
different regulations and rules upon the final product
variant (drug product in packaging) creating variety
regarding packaging. Patients are thus divided into
large segments to achieve economies of scale. Govender
et al. (2020a) conclude that current manufacturing plat-
forms are insufficient concerning affordability if pro-
duction volumes per variant are decreased.
Approaches to personalised medicines
Research within the field of personalised medicines has
primarily considered technical solutions for patient-
centric product design or efficient management of the
consequential growing complexity of the product port-
folio within manufacturing. The growing complexity
challenge has been addressed by, for example, Srai et al.
(2015), O’Connor et al. (2016) and Harrington et al.
(2016), with the focus to introduce novel technologies
into production, specifically continuous production.
These studies failed to consider a complete end-to-end
level assessment incorporating distribution and patient
provision.
Complexity as a consequence of customisation
Customisation, and the resulting increase in product
variants, has a crucial consequence on complexity as
pointed out by Stäblein (2010). An increasing number
of product variants require an increasing number of
product designs, parts as well as manufacturing pro-
cesses for these parts and products, not to disregard the
management of these parts and products throughout
the supply chain, any resources required to operate the
processes, to design the products and create the final
variety in products and so forth. These are a few rea-
sons for the growing complexity of a larger product
variety and thus, increasing the difficulty of managing
the growing product variety (Kvist, 2010).
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Concurrency in design. Kvist (2010) further emphasized
the importance in clarifying the connections of the
product design and the remaining phases of the prod-
uct lifecycle and various approaches to express these
interactions have been proposed by for example, Kvist
(2010) and Prasad (2016). Concurrent activities have
regularly been adopted to improve performance.
Landahl et al. (2020) proposed an approach to concur-
rency in product design tasks by integrating dynamic
product and production modelling to eliminate the risk
of late and costly product design changes propagating
to production in sequential product development.
Hence, the customisation of products for product
improvement, increasing the final complexity of the
overall product portfolio, is crucial to connect to the
operational aspects that are affected from this change
on phases beyond the product design domain.
Complexity and operational performance. Identifying con-
nections enabling the analysis of the consequences of
product portfolio complexity on the operational per-
formance of phases beyond product design is crucial to
enable an end-to-end analysis. Complexity and opera-
tional performance have been discussed, for example
by Stäblein et al. (2010) where the influence of com-
plexity on manufacturing costs, lead times and so forth
was presented. Trattner et al. (2019) performed a sys-
tematic literature review on the consequences of prod-
uct complexity on operational performance concluding
that product complexity has not only an unfavourable
effect on cost and time but also the quality and delivery
reliability, even though less clearly. Trattner et al.
(2019) also provided a discussion regarding the com-
plexity of the product portfolio and the increased risk
of errors in operations, product quality issues as well
as increasing errors from manual handling.
Mass customisation: A remedy of the growing complexity. Mass
customisation (MC) in a pharmaceutical context has
been hypothesised as a solution to enable the commer-
cialisation of personalised medicines to mitigate com-
plexity. Hu (2013) discussed three principles of MC:
modular product architectures, reconfigurable manu-
facturing systems and postponement or delaying differ-
entiation, each of which supports managing or
mitigating complexity arising from the customisation
demand of products. According to Kvist (2010), the
key to effective production of product variety is to
postpone the differentiation to the latest possible point
in the supply chain hence, the complexity mitigation
strategy focused on in this paper is postponement.
Gaps in the literature
There is, to the best of our knowledge, a lack of sys-
tem-level, end-to-end approaches assessing the conse-
quences of supply chain operations in a pharmaceutical
product customisation context. An end-to-end assess-
ment is required to understand the consequences of
transition towards a personalised medicines paradigm,
where the number of product variants is substantially
increasing. This paper provides an understanding of the
consequences of operational performance when intro-
ducing a customised product portfolio into a currently
operating pharmaceutical supply chain. Furthermore,
there is a lack of approaches addressing the operational
weaknesses of a currently operating supply chain in a
customisation context and thus, this paper aims at
addressing this gap by the usage of the MC principle of
postponement and suggesting reconfigurations to the
pharmaceutical supply chain by moving the point of
variegation, that is, the point in the supply chain where
the parts become dedicated to a product, to provide
remedy for the posed difficulties in operation.
The pharmaceutical supply chain
The main supply chain actors of the current pharma-
ceutical supply chain, called as-is design throughout
this paper, include the secondary manufacturer, whole-
saler, retailer (pharmacy), physician and patient
(Aitken, 2016; Olson, n.d.; Savage et al., 2006; Shah,
2004). Figure 1 displays the design of the pharmaceuti-
cal supply chain and a detailed description of the supply
chain actors, the transformation of the pharmaceutical
product throughout the supply chain as well as the
main functions of the actors – contributing to the trans-
formation of the product follows.
The upper bar, in Figure 1, displaying the supply
chain actors illustrates their communication path as
well as the physical journey of the pharmaceutical prod-
uct throughout the chain. The physician is not placed in
the upper bar since the physician is not physically in
contact with the product. The transformation of the
pharmaceutical product is described by the ellipses
labelled A to J. Figure 2 aims at clarifying the nature of
product variety throughout the transformation phases
– limited to crucial phases of the product transforma-
tion. Drug product (DP) refers to the finalised dosage
form, that is, the tablet, while FDP denotes final drug
product, referring to market-ready DPs, that is, pack-
aged and labelled accordingly. The activities transform-
ing the product are described in the rectangles and
numbered within parenthesis, such as (X.X), according
to the actor performing the activity, which follows the
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numbering of Figure 1. The nature of the product
resulting from the transformation performed by a sup-
ply chain actor is described and denoted within par-
enthesis (X) following the labelling in Figure 1.
The pharmaceutical supply chain is only regarded
downstream from the secondary manufacturer, which
transforms raw materials into FDPs (Savage et al.,
2006; Shah, 2004). This secondary manufacturer’s pri-
mary function is divided into three activities, firstly
manufacture DP (1.1), where raw materials (A), that is,
active and non-active ingredients are converted into
administrable tablets, DPs. Tablets can vary regarding
contents, size, shape, etc. (C) and are packed into inter-
mediate packaging for transfer to the assembly process.
The second activity produce packaging (1.2), converts
packaging material (B) into primary, secondary and
tertiary packaging (D). Primary packaging is the blister
pack sealing the tablets. Secondary packaging collects
the blister packs into a market-ready packaging incor-
porating information leaflets about the DP. The ter-
tiary packaging is aimed for bulk packaging enabling
convenient management of the products downstream
the supply chain (Savage et al., 2006). These package
types require printing and labelling to identify and
inform about the DP according to manufacturer brand-
ing and country-specific requirements (Savage et al.,
2006). Packaging DPs into respective packaging occurs
during activity (1.3) assemble FDPs, resulting thus in
FDPs. In Figure 2, for example for product variety E a
five-point star is placed by the FDPs. This star appears
to the right of the labelling of product variants 1, 2 and
M to mark the variety due to country-specific require-
ments. This means that various packaging is produced
for the same DP (Shah, 2004).
The FDPs (E) are purchased by the wholesaler from
various manufacturers, that is, procure FDPs (2.1). The
wholesaler bundles and resells the FDPs (F) to pharma-
cies (Derecque-Pois, 2010; Shah, 2004). Product variety
is created from various manufacturers not to disregard
identical DPs acquired from various manufacturers
(European Alliance for Access to Safe Medicines, n.d.;
Olson, n.d.; Shah, 2004). This is illustrated in Figure 1
by a matrix displaying 1 to M product variants from A
to N manufacturers. The distinction between manufac-
turers is achieved by colour coding the symbol for labels
and information leaflets and so forth. The wholesaler
activities are compiled under the expression manage
FDPs (2.2).
The physician function in this study is limited to the
activity of prescribing treatments for patients (3.1) from
making a diagnosis of the patient, resulting in a pre-
scription statement (G) communicated to the phar-
macy. This describes which DPs the patient shall
receive.
The patient acquires their prescription at the phar-
macy, whose primary function is to provide the patient
with the FDPs (F) according to the physician’s pre-
scription statement (G). This function incorporated the
activities: dispense FDPs (4.1), that is, dispensing FDPs
to the patient; manage FDPs (4.2) which includes activ-
ities from procuring FDPs to stocking products to
respond to uncertain demand for product variants
(Aitken, 2016; Olson, n.d.). Furthermore, ensure patient
safety (4.3) is a primary function of a pharmacist to
ensure the safety of a treatment which includes activi-
ties of correcting prescription errors made by the physi-
cian, counselling the patient on side effects and the
treatment’s dosing procedure and so forth (European
Figure 1. The as-is scenario of the pharmaceutical supply chain illustrating the path of the product transformation throughout it.
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Alliance for Access to Safe Medicines, n.d.; Olson,
n.d.). Overall, the nature of product variety when
received by the patient (H) is a function of the product
varieties (F) and (G) as well as any variety created by
the pharmacist when correcting prescription errors.
The patient activities include acquire FDPs (5.2), this
study expects the patient to acquire the prescription at
the pharmacy, and administer DP (5.1), which refers to
swallowing the tablet, hence, inducing a treatment out-
come (J) of the patient. Furthermore, the patient might
Figure 2. Illustrations of the nature of the product variety for a few crucial supply chain phases.
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need to interfere with the treatment before administra-
tion, for example, splitting tablets, administering multi-
ple tablets or combining treatment with food
(Govender et al., 2020a; Verrue et al., 2011). This inter-
fering activity is called finalise the assembly of DPs
(5.3). Thus, the final variety in treatment outcome (J) is
affected by the variety of FDPs received at the phar-
macy (H) and patient interference (I).
A few crucial concepts have been displayed in Figure
1, the point of variegation, the customer decoupling point
and the point of provision. A black circle marks the
point of variegation and represents the process step
when the product embraces its final configuration, that
is, where parts become dedicated to a product instance.
This point is positioned by the patient in the as-is
design of the supply chain. The point of provision, like-
wise, marked by a black circle, represents the position
in the supply chain where the patient acquires the treat-
ment. The customer decoupling point, marked by a black
triangle, denotes the step when the demand for product
variants is clarified. This demand is communicated by
the physician in the form of patient prescriptions.
Results
This section discusses the results of executing the
research activities presented in the Research approach-
section. The collected operational performance criteria
and the approach to performance assessment are
described and the operational performance of the as-is
design in a customisation context is presented. The
reconfigured supply chain designs are detailed and
finally, the operational performance assessment of
these designs is presented.
As mentioned, ambiguities in the entailed customisa-
tion level in a paradigm of personalised medicines
remains. The level of customisation assumed in this
study, for each customisation scenario discussed, is illu-
strated in Figure 3, with the nature of product variety
labelled H-Customised, which visualises a type of pill
organiser assembled before patient C acquires the pre-
scription at the point of provision.
The performance criteria and the approach to
performance assessment
The collected performance criteria are divided into five
categories: the cost of operation, time-to-patient, qual-
ity assurance, degree of process change and value for
the patient. Cost of operation covers the operational
costs that can be translated into monetary values; time
to patient measures the interval from diagnosis of the
patient (i.e. when the physician writes a prescription) to
treatment acquisition by the patient; quality assurance
covers activities ensuring that product integrity is
retained; degree of process change describes the reconfi-
gurations required by the supply chain to enable opera-
tion in a reconfigured mode while value for the patient
describes the patient benefit. The break-down and defi-
nitions of these categories are summarised in Table 1.
The performance assessment approach follows the con-
cept screening method by Ulrich and Eppinger (2012)
where concepts are compared to a reference concept
and for each criterion, a ‘+ ’, ‘2’and ‘0’ is assigned for
the concept. A ‘+ ’ indicates a favourable change, ‘2‘
an unfavourable change and ‘0’ indicates no change or
a non-conclusive comparison when comparing the per-
formance of the current concept to the reference con-
cept. Finally, the net value, that is, the sum of ‘2‘:s
deducted from the sum of ‘+ ’:s, is calculated to give
an overall indication on the how well the concepts per-
form compared to the reference.
The performance of the as-is design of the supply
chain in a customisation context
When assessing the performance of the as-is design in a
customisation context, the supply chain design is kept
intact. The position for H-Customised in the supply
Figure 3. The nature of product variety provided to the patient in a paradigm of personalised medicines.
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chain coincides with product variety in position H in
Figure 1 for the as-is design scenario (i.e. in an MP para-
digm, the patient acquires a product of product variety
level H, while in a customisation scenario, the patient
acquires a product of product variety level H-Customised).
The resulting performance assessment when operating the
as-is design of the supply chain in a customisation context
is displayed in Table 1 and an explanation follows where
each performance criteria, as well as the change to these,
have been highlighted using bold text.
For the category cost of operation, each criterion
results in unfavourable change except for capital invest-
ments, where no change is assumed. An increase in
product portfolio complexity results in an increase in
the number of changeovers during production, hence
an increase in equipment downtime resulting in a
decrease in capacity utilisation (Wilson, 2016). The as-is
design is assumed to operate in alignment with the cur-
rently operating functions of the supply chain actors to
the extent possible, and hence no change is expected in
the criterion capital investments. An increase is expected
for the criterion inventory, because although the stock
levels per product might remain unchanged, an increase
in the number of product variants requires additional
stocks of these variants – increasing the inventory
levels. An increase in material consumption is assumed
due to the more diverse range of material purchases
enabling the production of additional product variants.
A consequential risk includes increased expirations of
products, thereby accumulating waste and unnecessary
material consumption (Price Waterhouse Coopers,
2011; Shah, 2004). For the economy of scale criterion, a
decrease is expected, while economy of scale is achieved
in an MP context by defining large patient segments
(i.e. large groups of patients receiving the same treat-
ment). In a customisation context, the economies of
scale are challenged by a larger variety of smaller prod-
uct volumes for smaller patient segments (Govender
et al., 2020a; Wilson, 2016).
An unfavourable change is expected for time to
patient when operating the supply chain in a customisa-
tion context due to the unfavourable change in opera-
tional lead time and delivery complexity. An increase in
operational lead time is expected due to more frequently
interrupted operational flow resulting from a larger
product variety and additional handling and moving of
parts and products (e.g. Stäblein, 2010; Trattner et al.,
2019; Wilson, 2016). Delivery complexity is assumed to
increase, because a more complex product portfolio is
delivered in a customisation context instead of
Table 1. The performance criteria and the assessment of the as-is design operating in a customisation context.
Performance criteria Definition Assessment
Cost of operation Capacity utilisation The utilisation level of the existing operational capacity –
Capital investments Any required capacity expansions in the supply chain
operation
0
Inventory The stock levels of parts or products kept by the supply
chain actors
–
Material consumption The consumption of diverse materials during operation –
Economy of scale Cost advantages of producing higher volumes of product
variants
–
Time to patient Operational lead time The time of operation –
Delivery complexity The complexity of goods delivery to subsequent supply
chain actor
–
Quality assurance Effort in quality control Activities performed to ensure product quality in the
supply chain
–




within a supply chain node
New technologies or activities required in the operation
of a supply chain actor, for example, the education or




The level of operational alignment of the supply chain
operating in a customisation context with the supply chain




Treatment outcome The outcome of the treatment that the patient administers þ
Patient effort The effort required from the patient to achieve a certain
treatment outcome, for example, acquiring prescriptions,
splitting tablets and, any disregarded dosages due to





The net value 27
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delivering large bulks of products to the subsequent
supply chain actor.
An unfavourable change is expected for the quality
assurance category. An increased effort in quality con-
trol is expected due to smaller batches, which increase
the number of quality inspections since each batch
requires quality assurance (Rantanen & Khinast, 2015;
Trattner et al., 2019). The risk of errors increases with
the increasing number of processes, operations and
work tasks to be managed throughout the supply chain
(Trattner et al., 2019).
An unfavourable change is expected for degree of
process change due to the criterion new working proce-
dures within a supply chain node because a need for
additional support tools and education is assumed to
manage the increasing complexity of the product port-
folio. No change is assumed for the criterion new work-
ing procedures across nodes since the as-is design of the
supply chain is retained, and thus no new communica-
tion channels across nodes are established.
Value for the patient clarifies the benefit of persona-
lised medicines, and Table 1 shows that a favourable
change is expected for each criterion in this category.
When operating the as-is design in a customisation con-
text, it is assumed that the patient receives treatment
according to their needs and preferences (product vari-
ety H-Customisation, see Figure 3), which increases the
criterion treatment outcome. In addition, interference
with the treatment before administration is disregarded
thus making the activity finalise the assembly of DPs
(5.3) in Figure 1 redundant and consequently also the
arising product variety I. variety of patient interference.
This entails a decrease in patient effort since the treat-
ment is matched to their needs and preferences without
patient interference (Govender et al., 2020; Wilson,
2016).
To summarise the results of Table 1– a net value of
27 was obtained indicating that operating the as-is
design of the supply chain in a customisation context is
not a feasible solution. To acquire the benefits of pro-
ducing customised pharmaceutical products, that is, to
improve the treatment outcomes of the patients, conse-
quences of operating the pharmaceutical supply chain
are expected and challenge the transition to a paradigm
of personalised medicines:
 Increasing costs, time to patient and effort in qual-
ity assurance activities.
 Increased degree of process change, that is, alterna-
tive technical solutions are required to enable man-
aging the increased complexity of the product
portfolio.
Reconfigured supply chain designs for a mass
customisation context
Table 2 presents four reconfigured supply chain
designs. In each scenario, the customer decoupling point
aligns with the point of variegation which was not the
case of operating the as-is design in an MP context.
Four reconfigurations are presented: the MTO, MI,
ATO and DD scenarios. The position of the point of
variegation is varied in each scenario.
Figure 4. A conceptual sketch of the sources of variety in each supply chain scenario.
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Table 2 marks the point of variegation with the sym-
bol ‘O’. The nature of product variety managed in each
supply chain phase is displayed in Table 2 and is refer-
enced by the labelling presented in Figures 1 to 3 within
brackets, for example, (X). In addition, the evolution of
the product portfolio complexity is displayed in Figure
4 and accompanied by product variety sources in each
supply chain phase. The purpose of the sketch is to
overview the product portfolio complexity for each sce-
nario, and thus the absolute level of complexity for the
scenarios has not been clarified, and the complexity lev-
els are not to scale and not comparable in absolute
values.
Any changes to the operational scope of the supply
chain by the reconfigured designs are displayed in
Table 2, and their numbering follows that of Figure 1.
New activities required to be performed by the actors
in the reconfigured mode are likewise displayed in
Table 2 and subsequently discussed.
While reconfiguring the supply chain, the assump-
tion is that the patient acquires a finalised customised
treatment, nature of product variety (H-Customised),
eliminating the need of patient interference with the
product, similarly to the as-is design operating in an
MC context. The function 5.3, finalise the assembly of
DPs, is thus eliminated for each reconfigured design,
which also eliminates any product variety arising from
this activity, that is, I. variety of patient interference, as
displayed in Figure 1.
The make to order scenario. The idea of the make to
order (MTO) scenario is to create the final product
variety, that is, performing the final assembly, where
the assumed knowledge for this activity exists, that is,
by the secondary manufacturer (the secondary manu-
facturer is assumed to be the most knowledgeable
regarding drug production). No new activities are thus
needed in the supply chain. The point of variegation is
placed by the secondary manufacturer, and the physi-
cian is set to communicate directly with the secondary
manufacturer, setting the demand for the product
portfolio.
The difference between the MTO and as-is design is
that in the MTO scenario, the market-ready prescrip-
tions (H-Customised) are finalised by the secondary
manufacturer according to patient needs, whereas in
the as-is design scenario, the final bundling of product
variants to satisfy the patient needs according to the
prescription (H-Customised) occurs at the pharmacy.
Thus, the secondary manufacturer must provide for
any product variant required by a patient for any dis-
ease, which requires the secondary manufacturer to
expand production to incorporate all treatments,
adjusting 1.1 Manufacture DP, 1.2 Produce packaging
and 1.3 Assemble FPs (also see Figure 4 for product
portfolio complexity). This would also require a pre-
made selection of the secondary manufacturer to pro-
duce the treatment, however, this consideration is
outside the of this paper. No final bundling of
Table 3. The performance assessed for each reconfigured supply chain design as a comparison to the as-is design operating in a
customisation context.
Performance criteria As-is design
customisation
context
MTO MI ATO DD
Cost of operation Capacity utilisation 0 – 0 þ 0
Capital investments 0 – – – –
Inventory 0 þ þ þ þ
Material consumption 0 þ þ þ þ
Economy of scale 0 – þ þ þ
Time to patient Operational lead time 0 – 0 þ 0
Delivery complexity 0 – 0 þ –
Quality assurance Effort in quality control 0 – 0 þ –
Risk of errors 0 – 0 þ –
Degree of process change New working procedures
within a node
0 0 – – –
New working procedures
across nodes
0 0 – – –
Value for the patient Treatment outcome 0 0 0 0 0
Patient effort 0 0 0 0 þ
Sþ 0 2 3 7 4
S– 0 7 3 3 5
S0 13 4 7 3 4
The net value 0 –5 0 þ4 –1
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prescription occurs at the pharmacy in the MTO sce-
nario, the activity 4.1 dispense FPs is adjusted to solely
cover the dispensation activity.
The secondary manufacturer in the MTO scenario
must provide for any product variant as well as
patient-specific packaging needs (H-Customised).
Standardisations such as multipurpose packaging and
information leaflets are not possible, which increases
the final complexity of the product portfolio by the sec-
ondary manufacturer (nature of product variety E)
thus further, requiring the management of a product
portfolio of increased complexity, 2.2 and 4.2, down-
stream the supply chain.
The manufacturer integrator scenario. The idea of the man-
ufacturer integrator (MI) scenario is to bundle DPs
from manufacturers early in the supply chain resem-
bling the operating model of the retail corporation
Walmart Inc. A standardised portfolio of DPs (C) is
delivered from the secondary manufacturer to the
wholesaler, who finalises the product assembly (H-
Customised), A. finalise FDP assembly, after the pre-
scription order by the physician has been placed and
thus the activity 2.2 manage FDPs is adjusted.
Furthermore, the production effort of the secondary
manufacturer is reduced as bulks of DPs in intermedi-
ate packaging (C) are produced rather than finalised
FDPs thus, activities 1.2 and 1.3 are adjusted as well as
the activity of final packaging production needs to be
reallocated. In Table 2, the category ‘reallocated func-
tions’ is displayed and lists the function i. produce
packaging.
The position of the activity A. finalise FDP assembly
at the wholesaler enables treating DPs with identical
product formulation procured from various manufac-
turers as the same product variant – the activity 2.1 pro-
cure FDPs is adjusted. This decreases the number of
variants in the product portfolio – eliminating the N-
dimension in the matrix for product variety (F) (see
Figure 2).
If the wholesalers operate in strategic positions close
to the market the product portfolio complexity can be
further reduced since the need to create packaging ser-
ving several markets is eliminated – eliminating the
dimension denoted by the five-point star for product
variety (E) in Figure 2. The complexity of the final
product variety is thus lower for the MI scenario com-
pared to the as-is design scenario (see Figure 4); how-
ever, the complexity of the product portfolio leaving
the wholesaler is supposedly higher when comparing
the MI to the as-is design scenario, because, in the lat-
ter, the patient-specific prescriptions have not yet been
finalised.
Due to the pharmacy facing larger product variety
in orders from the wholesaler in the MI scenario com-
pared to the as-is design scenario, the managerial effort
of the pharmacy is increased, 4.1, but the activity of
final bundling various product variants according to
patient-specific prescriptions is eliminated (which is the
case in the as-is design of transforming (F) into (H-
Customised)).
The assembly to order scenario. The assembly to order
(ATO) scenario simulates an environment where the
final assembly is placed closest to the patient. The
operating model of the restaurant franchise Subway
resembles the ATO scenario, which includes the advan-
tages of the MI scenario up to the point of the whole-
saler; however, a later point of variegation placed by
the pharmacy provides additional advantages such as
managing a less complex product variety (C) further
downstream the supply chain (bulks of DPs in inter-
mediate packaging are managed throughout the supply
chain to the pharmacy, see Figure 4). The strategic
positions of pharmacies by the market served also elim-
inates the requirement of diverse packaging, thereby
eliminating the source to variety denoted by a five-
point star in Figure 2 for product variety (E).
The pharmacy can be characterised as a compound-
ing pharmacy, transforming bulks of DPs in intermedi-
ate packaging (C) into prescription-ready orders of
FDPs (H-Customised). Hence, the pharmacy operates
a new activity A. finalise FDP assembly (see Table 2).
Furthermore, a reallocation is required for the activity
of providing for final packaging i. produce packaging.
The communication channel of the actor providing for
this activity is established towards the pharmacy.
The direct delivery scenario. In the direct delivery (DD)
scenario, the point of variegation is placed by the
wholesaler similarly to the MI scenario; however, direct
delivery of the finalised, prescription-ready products to
the point of the patient from the product configuration
site is proposed. This design resembles the business
model of the computer technology company Dell. A
decreased effort by the patient is expected, thereby
eliminating the function of 5.2 acquire FDPs. An alter-
native delivery channel for the products is, however,
required, and a function ii. product delivery is displayed
for ‘reallocated activities’ in Table 2.
Direct delivery to patients eliminates physical con-
tact of the pharmacy with the product, which Table 2
displays as black cells by the pharmacy. The activity
4.3 ensure patient safety falls within the category ‘real-
located functions’ in Table 2 since this activity is crucial
and hence, needs to be provided by other means.
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Operational performance of the reconfigured supply
chain designs
The results from assessing the operational performance
of each reconfigured supply chain design are presented
in Table 3. As a reference concept, to which each recon-
figured design has been compared, the as-is design has
been used. For the performance criteria and the
approach to performance assessment, a description is
provided in the section titled ‘‘The performance criteria
and the approach to performance assessment’’.
Cost of operation. Decreased capacity utilisation repre-
sents a consequence of an increased product portfolio
complexity. For the MTO scenario, a higher product
portfolio complexity throughout the supply chain
results in lower capacity utilisation, thus, an unfavour-
able change is expected. For the MI scenario, the prod-
uct portfolio complexity is assumed to surpass the as-is
scenario at the wholesaler; however, to be surpassed by
the as-is scenario at the secondary manufacturer and
the pharmacy. Hence, a non-conclusive comparison
between the MI scenario and as-is design is given in
Table 3. The ATO scenario embraces a lower product
portfolio complexity throughout the supply chain, and
higher capacity utilisation is thus expected in the ATO
scenario, resulting in a favourable change. The product
portfolio complexity of the DD scenario follows the
MI scenario up to the wholesaler. In the DD scenario,
the capacity of the pharmacy is not needed, but there is
a required capacity for delivering the products directly
from the wholesaler to the point of provision. Hence, a
conclusive comparison between the DD scenario and
the as-is design is not provided.
Considering the criterion capital investments, a need
to invest in additional capacity at the secondary manu-
facturer for the MTO scenario is expected, resulting in
an unfavourable change. The MI, ATO and DD scenar-
ios are expected to require capital investments within
the operations where new activities are introduced in
the supply chain, such as the activity of A. finalise FDP
assembly introduced in Table 2, likewise resulting in
unfavourable changes.
Placing the customer decoupling point by the point
of variegation, and early in the supply chain provides
the best conditions to optimise production to the
demand of product variants. A better match of produc-
tion to this demand implies reduced inventory levels
since safety stock is not needed to a similar extent, for
example. Like inventory levels, a better match to the
actual product demand is assumed to optimise material
consumption and decrease risks of stock expiration.
Hence, reduced inventory levels and material
consumption are expected for the MTO, MI, ATO and
DD scenarios, thus resulting in favourable changes for
each scenario concerning these criteria.
Keeping the nature of product variety as bulks of
DPs in intermediate packaging (product variety level
C, see Figure 2) and regarding DPs similar in formula-
tion as the same product variant is assumably condi-
tioning achieving economy of scales. Larger volumes of
fewer product variants characterise the MI, ATO and
DD scenarios and results in favourable changes. In the
MTO scenario, patient-specific product variety is cre-
ated by the secondary manufacturer, which minimises
the potential of achieving an economy of scale and thus
an unfavourable change is expected for this criterion.
Time to patient. A decreased capacity utilisation is
expected thereby also increasing the operational lead
time. The same reasoning as for the criterion capacity
utilisation, within the category cost of operation, thus
applies for each reconfigured scenario. Due to the
increased complexity of the product portfolio, a higher
delivery complexity for the MTO scenario is expected.
The resulting comparison provided between the MI
and as-is design is non-conclusive with the same rea-
soning regarding the product portfolio complexity as
for capacity utilisation. In the ATO scenario, a lower
complexity is managed – bulks of DPs in intermediate
packaging, and hence a favourable change is expected.
The product complexity of the DD scenario behaves
similarly to the MI scenario; however, the products are
directly delivered from the wholesaler to the patient,
significantly increasing the complexity of delivery to
the point of provision and thus an unfavourable
change is expected for this scenario.
Quality assurance. A product portfolio of increased com-
plexity implies an increasing number of batches of
lower volumes that need to be controlled for quality,
thereby increasing the effort in quality control. An unfa-
vourable change is thus expected for the MTO sce-
nario. No conclusive comparison for the MI scenario is
provided due to the indecisive comparison of the prod-
uct portfolio complexity between the MI and as-is
design scenarios throughout the supply chain. The
lower complexity of the product portfolio for the ATO
scenario is expected to result in a favourable change
for this criterion. In the DD scenario, the effort to con-
trol quality is assumed to be increased, resulting in an
unfavourable change due to the new approach of prod-
uct delivery to the point of provision. For each reconfi-
gured supply chain design, the same reasoning for the
criterion risk of error applies as in the criterion effort in
14 Concurrent Engineering: Research and Applications 00(0)
quality control since this risk is increased with an
increasing product portfolio complexity.
Degree of process change. As stated in Table 2, the func-
tion A. finalise FDP assembly is introduced to be oper-
ated by actors in the supply chain scenarios MI, ATO
and DD. Introducing new functions is expected to
result in an increased need for resources in the form of,
for example, educational needs, re-shaping the organi-
sations’ operations and additional capital investments
required for operation (also discussed under the criter-
ion capital investments). This increase in resources is
captured in the criterion new working procedures within
a supply chain node and thus results thus in unfavour-
able changes for the MI, ATO and DD scenarios.
The criterion new working procedures across nodes is
visible in Table 2 as the category ‘reallocation of func-
tions’ and implies efforts required to enable realising
the respective functions requiring reallocation, for
example, the need of providing for customised packa-
ging for the assembly process when moved to a supply
chain position not already executing such an activity.
Reallocation of functions is required for the MI, ATO
and DD scenarios, thereby resulting in unfavourable
changes for this criterion.
Value for the patient. In each supply chain scenario oper-
ating in a customisation context, the patient is offered
a treatment embracing the product nature of H-
Customised (see Figure 3). Thus, the treatment outcome
is the same in each supply chain scenario and thus no
change is expected for this criterion. Risk of treatment
misuse is possible after receiving the treatment before
administration, but this is not considered here. The
only scenario inducing a change in the criterion patient
effort is the DD scenario due to eliminating the need
for the patient to acquire their prescriptions at a phar-
macy and instead receiving a direct delivery. Thus, a
favourable change is expected for this criterion.
Summary of the results from the performance
assessment. The results in Table 3 show that the ATO
scenario displays the best performance compared to
the as-is design as a reference solution – the net value
+4. A later point of variegation provides for the
strength of this scenario since a product portfolio of
low complexity is managed throughout the supply
chain. This implies decreased costs of operation, lead
times and efforts towards quality assurance activities.
However, the weaknesses of the ATO scenario are the
requirement of new functions in the supply chain
actors’ operations and reallocated functions. The per-
formance of the MI scenario results in the same net
value – 0, as the as-is design; however, this assessment
is performed as a comparison to a single reference solu-
tion and without consideration of how well the scenar-
ios perform in each criterion or their comparative
importance. In addition, due to the trade-offs within
the supply chain and the entailed comparison difficulty
between the supply chain designs regarding the perfor-
mance criteria, the results displayed in Table 3 repre-
sent an indication solely.
Discussion
To answer the first research question, RQ1, ‘What are
the operational weaknesses of the current pharmaceuti-
cal supply chain design when operated in a pharmaceu-
tical product customisation context?’ The results in
Table 1 and the result analysis the section ‘‘The perfor-
mance of the as-is design of the supply chain in a custo-
misation context’’ shows that the inevitable increase in
product portfolio complexity leads to increased costs in
operation, time of supplying products to patients and
efforts required for ensuring product quality.
Furthermore, alternative solutions are required to
enable managing the increased complexity of the prod-
uct portfolio. The third research question, RQ3, ‘How
can the pharmaceutical supply chain be reconfigured to
address the operational weaknesses of the currently
operating supply chain’ was posed to remedy the weak-
nesses elicited by RQ1. To answer RQ3 three key
insights will be presented for consideration of supply
chain reconfiguration:
Key insight 1: The position of the point of variegation is
crucial to consider since it affects the final complexity
of the product portfolio to be managed throughout the
supply chain. A strategic position, close to the market,
mitigates portfolio complexity by eliminating, for
example, country-specific labelling or distinction
between DPs with the same formulation but from dif-
ferent manufacturers (if placed by the wholesaler or
later), scenarios ATO, MI and DD. According to
Verhasselt and Friemann (2012), pharmaceutical prod-
uct characteristics are largely identical for purely man-
ufactured DPs from various manufacturers, and the
increased complexity originates from the packaging of
the DPs due to their need to display manufacturer
brands. Furthermore, the position for the point of var-
iegation divides the supply chain concerning opera-
tional performance. Phases before this point perform
better compared to the phases following afterwards
regarding the operational performance criteria capacity
utilisation, economy of scale, operational lead time,
effort in quality control and risk of errors. The complex-
ity of the product portfolio grows in the point of
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variegation, hence, the later in the supply chain the
point of variegation is placed, the better the overall per-
formance concerning these abovementioned criteria,
see scenario MI.
Key insight 2:Alignment with the currently operating
supply chain design represents another parameter for
consideration when reconfiguring the supply chain.
Deviations require, for example, education of the sup-
ply chain actors to be able to operate the new design,
capital investments into new technologies or capacities,
ensuring safe product delivery to the patients and prob-
able introductions of new communication channels
with new supply chain actors. Overarching trade-offs
integrating the operational and business levels require
consideration. Improving operational performance, for
example, by pushing the point of variegation to the
point of provision (see the ATO scenario) results in an
increased degree of process change, that is, a higher
level of reconfiguration of the supply chain, meaning
reallocating activities, introducing new activities, estab-
lishing new communication channels and so forth.
Key insight 3:Effort by the patient refers to the effort
exerted by the patient to achieve the same treatment
outcome and should incorporate the consideration of
treatment acquisition, that is, if the patient acquires the
prescription at the pharmacy or if the treatment is
delivered to the point of the patient, that is, the DD sce-
nario. Studies have shown concerns related to the rate
of prescriptions acquired at the pharmacy; for example,
a white paper by NEHI (the network for excellence in
health innovation) in 2014 states that up to 30% of
prescriptions for certain medications of first-time pre-
scriptions are left on pharmacy shelves. The final
assembly performed by the patient shall be considered.
Reducing patient interference with the treatment is
assumed to enhance the therapeutic outcome, verified
by widespread research considering patient adherence
and compliance, for example, Klingmann et al. (2020)
and Hofmanová et al. (2020). In this study, each supply
chain operating in a customisation context functions
with the assumption that the patient acquires a fully
customised product, with the consequence of increasing
operational effort. A trade-off concerning the responsi-
bility given to the patient regarding the final treatment
assembly and the consequences on supply chain opera-
tions if eliminating patient interference shall be
investigated.
To answer the second research question, RQ2, ‘Which
operational performance criteria can be used to assess
the performance of the pharmaceutical supply chain
operating in a customisation context?’, the performance
criteria were divided into five categories: cost of
operation, time to patient, quality assurance, degree of
process change and value for the patient, with the full
set of criteria with respective definitions presented in
Table 1. This set represents initially suggested criteria
for assessing the performance of pharmaceutical supply
chain designs operating in a customisation context and
is a result of literature studies as well as discussion with
industrial practitioners. Due to the subjectivity of the
selection of performance criteria, future studies to
determine whether the correct criteria were collected is
suggested.
The criteria were used to qualitatively assess the per-
formance of the reconfigured supply chains and to
solely capture a better or worse performance of the
respective reconfigured supply chain design compared
to the as-is design. As a method, the concept screening
method by Ulrich and Eppinger (2012) was used. As a
next step, a quantitative approach shall be considered
for which Ulrich and Eppinger (2012) suggest the con-
cept scoring matrix. In this method, the level to which
the performance improves or worsens is assessed. In
addition, the importance of each performance criteria
is quantified by assigning weights to these. Improved
comparisons between various supply chain designs
could be achieved and support the choice of the best-
performing supply chain design. It is difficult to predict
opportunities for testing supply chain reconfiguration
in practice, but quantitative studies complemented with
an ongoing dialogue with industrial practitioners might
enhance the reconfigured supply chain designs.
The reconfigured supply chain designs were devel-
oped by studying successful business models beyond the
pharmaceutical model, with a focus on those addressing
customisation or a large product variety. A few business
models were selected and adapted into the pharmaceuti-
cal product context to represent archetypes of reconfi-
gured supply chain models. These archetypes were
discussed with a group of industrial practitioners and
thereby further refined. Better-suited business models
for pharmaceutical products in a customisation context
might have been overlooked.
The MC strategy postponement was addressed in this
study. However, approaches integrating modular prod-
uct architectures and reconfigurable manufacturing sys-
tems shall be considered for future work. Modular
product architectures are advantageous from the per-
spective of providing variety for customers, however,
the right level of modularisation shall be traded
towards cost considerations. For example, Askhøj and
Mortensen (2020) discuss the trade-off between part
commonality and distinctiveness to find the right num-
ber of product architectures for a company and Borgue
et al. (2019) discusses the trade-off between integral
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and modular product designs and their influence on
costs. In addition, product division supports the
approach to concurrent engineering (Prasad, 1999).
Reconfigurable manufacturing systems shall be consid-
ered as an approach to improve the efficiency, as sub-
optimizing production seldom solves the complexity
problem and thus, flexibility and reconfigurability into
manufacturing systems are advocated (ElMaraghy
et al., 2012).
This study uses the term personalised medicines for the
physical treatment, that is, the tablet received by the
patient, which is customised according to patients’ individ-
ual needs and preferences. The term customised pharma-
ceutical product is used interchangeably with personalised
medicines throughout the paper, and the level of intended
customisation coincides with H-Customised displayed in
Figure 3. To further discussions on the terminology within
the research field of personalised medicines and individua-
lised treatment reader is referred to the works of Govender
et al. (2020a).
Conclusions and future work
This study addresses the gap of no system-level, end-to-
end analysis of operating the pharmaceutical supply
chain in a customisation context. The results show that
operating the current pharmaceutical supply chain in a
customisation context implies:
 Increasing costs, time to patient and efforts in qual-
ity assurance activities.
 An increasing degree of process change, that is,
alternative technical solutions are assumed to be
required to enable managing the increased com-
plexity of the product portfolio.
To address these challenges, business models success-
fully managing high product variety or operating in an
MC paradigm were studied, which inspired reconfi-
gurations to the pharmaceutical supply chain. The MC
principle of postponement as a product portfolio com-
plexity mitigation strategy was used to adapt the busi-
ness models into a pharmaceutical product context.
Four reconfigured supply chain designs were suggested
and constituted configurations with the point of varie-
gation in varying locations of the supply chain. The
performance of these supply chain reconfigurations
was then assessed, with the results showing that:
 A strategically chosen position for the point of var-
iegation can reduce product portfolio complexity.
 The position of the point of variegation causes
trade-offs concerning performance within the sup-
ply chain.
 A trade-off between the level of customisation cre-
ated prior to patient provision and the patient
responsibility of performing the final customisation
shall be considered.
 A trade-off between the degree of reconfigurations
of the supply chain supporting an increased opera-
tional performance and keeping an alignment with
the current design to reduce the need of capital
investments in technology and education of supply
chain actors shall be considered.
A qualitative performance assessment of the reconfi-
gured supply chain designs has been performed, and
conducting quantitative studies is suggested to generate
knowledge regarding the feasibility of the designs. This
paper studied the MC principle of postponement as a
complexity mitigation strategy. Future studies should
integrate product modularisation strategies and con-
sider the flexibility of stakeholder operations required
to manage a product portfolio of growing complexity
in the pharmaceutical supply chain.
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